Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats

Jong, Trynke R. de; Snaphaan, Liselore; Pattij, Tommy; Veening, Jan G.; Waldinger, Marcel D.; Cools, Alexander R.; Olivier, Berend

doi:10.1016/j.euroneuro.2005.06.004

Cited by 50 publications

(51 citation statements)

References 53 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benzodiazepine anxiolytic diazapam exhibited no effects on apomorphine-induced PPI deficits in rats (de Jong et al , 2006; Rigdon, 1991) but it has been found to increase PPI in C57BL6J, a mouse strain that has naturally low PPI (Ouagazzal et al , 2001). With regard to the anticonvulsant mood stabilizer valproic acid, Ong et al (Ong et al , 2005) found that it had no effect on PPI in C57BL/6J mice, whereas Flood et al (Flood et al , 2009) reported that it increased PPI in DBA.2 mice, another strain with naturally low PPI.…”

Section: Discussionmentioning

confidence: 99%

Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy

Feifel

Melendez

2010

J Psychopharmacol

View full text Add to dashboard Cite

Our laboratory and others have reported that Brattleboro (BRAT) rats, a Long Evans (LE) strain with a single gene mutation, have inherent deficits in prepulse inhibition (PPI) homologous to those observed in schizophrenia patients and that these deficits are reversed by antipsychotic drugs (APDs). To further evaluate the potential predictive validity of BRAT rat PPI for APDs, we compared the effects of acute subcutaneous administration of the typical APD chlorpromazine to that of three psychotropic drugs without antipsychotic efficacy, the antidepressant imipramine, the anxiolytic diazepam and the anticonvulsant mood stabilizer valproic acid on male and female BRAT rat PPI. Male and female BRAT rats exhibited baseline (saline treatment) PPI that was not different from each other (21.1 % and 21.3 %, respectively) and low compared to those historically exhibited by LE rats (approximately 59 %). Chlorpromazine facilitated PPI in male and female BRAT rats, whereas imipramine, diazepam, and valproic acid had no significant effect on PPI. These results suggest that PPI in the BRAT rat responds specifically to drugs with APD efficacy but not psychotropic drugs of different therapeutic families.

show abstract

Section: Discussionmentioning

confidence: 99%

Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy

Feifel

Melendez

2010

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

“…It is possible as well, that PE populations may differ in some neurophysiological dimension, as compared to depressed or other clinical populations for whom SSRIs are commonly prescribed. However, post SSRI persistence of biological changes or adaptations can by no means be ruled out [8], are supported by animal studies [50][51][52], and thus ought to be a cause for concern.…”

Section: Critiquementioning

confidence: 99%

Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence

Bahrick

2008

TOPSYJ

View full text Add to dashboard Cite

Post-market prevalence studies have found that Selective Serotonin Reuptake Inhibitor (SSRI) and SerotoninNorepinephrine Reuptake Inhibitor (SNRI) sexual side effects occur at dramatically higher rates than initially reported in pre-market trials. Prescribing and practice conventions rest on the untested assumption that individuals who develop sexual dysfunction secondary to SSRI and SNRI antidepressant medications return fully to their pre-medication sexual functioning baseline shortly after discontinuing treatment. Most individuals probably do return to their previous level of sexual functioning, however recent case reports, consumer-provided Internet-based information, incidental research findings, and empirical evidence of persistent post SSRI sexual benefits in the premature ejaculation literature suggest that for some individuals, SSRI and SNRI-emergent sexual side effects persist indefinitely after discontinuing the medications. The literature poorly captures the full spectrum of SSRI/SNRI sexual side effects, and a lack of systematic follow-up in the sexual side effects research precludes detection of post SSRI/SNRI sexual dysfunction, leaving the formal knowledge base inadequate and even inaccurate, raising informed consent issues, and leaving clinicians vulnerable to practicing in ways that may be hurtful to patients in spite of their best efforts to inform themselves.

show abstract

“…Even though there are many children and adolescents with psychiatric disorders (Emslie and Mayes, 2001), decisions regarding the use of antidepressants in young people (such as the SSRIs) are still largely based on data from adults (Manfridi et al, 1992; de Jong et al, 2006). Efficacy measurements in humans recommend SSRIs as the initial medication of choice for young individuals in depression and for improving obsessive-compulsive disorder (OCD; Doogan and Caillard, 1988; Alderman et al, 1998; Emslie and Mayes, 2001; Moreno et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

The effects of sertraline administration from adolescence to adulthood on physiological and emotional development in prenatally stressed rats of both sexes

Pereira-Figueiredo

Sancho

Carro

et al. 2014

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Sertraline (SERT) is a clinically effective Selective Serotonin Reuptake Inhibitor (SSRI) known to increase and stabilize serotonin levels. This neurotransmitter plays an important role in adolescent brain development in both rodents and humans, and its dysregulation has been correlated with deficits in behavior and emotional regulation. Since prenatal stress may disturb serotoninergic homeostasis, the aim of this study was to examine the long-lasting effects of exposure to SERT throughout adolescence on behavioral and physiological developmental parameters in prenatally stressed Wistar rats. SERT was administered (5 mg/kg/day p.o.) from the age of 1–3 months to half of the progeny, of both sexes, of gestating dams stressed by use of a restraint (PS) or not stressed. Our data reveal that long-term SERT treatment slightly reduced weight gain in both sexes, but reversed the developmental disturbed “catch-up” growth found in PS females. Neither prenatal stress nor SERT treatment induced remarkable alterations in behavior and had no effects on mean startle reflex values. However, a sex-dependent effects of PS was found: in males the PS paradigm slightly increased anxiety-like behavior in the open field, while in females, it impaired startle habituation. In both cases, SERT treatment reversed the phenomena. Additionally, the PS animals exhibited a disturbed leukocyte profile in both sexes, which was reversed by SERT. The present findings are evidence that continuous SERT administration from adolescence through adulthood is safe in rodents and lessens the impact of prenatal stress in rats.

show abstract

Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats

Cited by 50 publications

References 53 publications

Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy

Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy

Persistence of Sexual Dysfunction Side Effects after Discontinuation of Antidepressant Medications: Emerging Evidence

The effects of sertraline administration from adolescence to adulthood on physiological and emotional development in prenatally stressed rats of both sexes

Contact Info

Product

Resources

About